title: Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm.
abstract: Staphylococcus epidermidis is a commensal inhabitant of the healthy human skin, but in the recent years, it has been recognized as a nosocomial pathogen especially in immunocompromised patients. The pathogenesis of S. epidermidis is thought to be based on its capacity to form biofilms on the surface of medical devices, where bacterial cells may persist, protected from host defence and antimicrobial agents. Rifampin has been shown to be one of the most active antimicrobial agents in the eradication of the staphylococcal biofilm. However, this antibiotic should not be used in monotherapy. Therefore, one of the objectives of our research was to study the efficacy of the tigecycline/rifampin combination against methicillin-resistant S. epidermidis embedded in biofilms. Of the 80 clinically significant S. epidermidis isolates, 75 strains possess the ability to form a biofilm. These bacteria formed the biofilm via ica-dependent mechanisms. However, other biofilm-associated genes, including aap (encoding accumulation-associated protein) and bhp (coding cell wall-associated protein), were present in 85 and 29 % of isolates, respectively. The biofilm structures of S. epidermidis strains were also analyzed in confocal laser scanning microscopy (CLSM) and the obtained image demonstrated differences in their architecture. In vitro studies showed that the MIC value for tigecycline against S. epidermidis growing in the biofilm ranged from 0.125 to 2 μg/mL. Tigecycline in combination with rifampin demonstrated higher activity against bacteria embedded in biofilms than tigecycline alone.
authors.affiliation: Department of Microbiology, Institute of Experimental Biology, Faculty of Biology, Adam Mickiewicz University, ul. Umultowska 89, 61-614, Poznań, Poland, ewasz@amu.edu.pl.
authors.forename: Ewa
authors.initials: E
authors.lastname: Szczuka
authors.forename: Adam
authors.initials: A
authors.lastname: Kaznowski
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018441:Biofilms / Q000187:drug effects / Q000254:growth & development*; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004359:Drug Therapy, Combination / Q000592:standards; D006801:Humans; D008826:Microbial Sensitivity Tests; D018613:Microscopy, Confocal; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013212:Staphylococcus epidermidis / Q000235:genetics / Q000254:growth & development*; D000078304:Tigecycline
chemical_list: D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D000078304:Tigecycline; D008911:Minocycline; D012293:Rifampin